casamento charles j  the wall street transcript charles j casamento charles j casamento is chairman president and chief executive officer of questcor pharmaceuticals inc he joined ribogene inc in june  on november   ribogene and cypros merged to form questcor pharmaceuticals inc the company currently has five products on the market in the us in the fourth quarter of  driven by the introduction of a new product nascobal questcor revenues hit a record level and the company recorded its first profitable quarter with net income of  mr casamento closed  partnership product acquisition rd collaborations and merger transactions with questcor previously mr casamento was president and chief executive officer of interneuron pharmaceuticals inc which he cofounded in february  from  to  he was senior vice president at genzyme corporation from  to  he was vice president business development and planning at the critical care division of american hospital supply corporation and from  to  he held managerial positions with johnson  johnson hoffmannlaroche and sandoz mr casamento received an mba in  from iona college new rochelle new york and a bs in pharmacy in  from fordham university college of pharmacy in new york city he is a member of the board of directors of cortex pharmaceuticals inc in irvine california supergen inc in dublin california and the catholic medical mission board a nonprofit organization in new york new york which serves the medical needs of people in third world countries he is a licensed pharmacist in the states of new york and new jersey related interviewscharles casamento  questcor pharmaceuticals inc qscmay  charles casamento  questcor pharmaceuticals inc qscoctober  charles casamento  questcor pharmaceuticals inc qscmarch  charles casamento  questcor pharmaceuticals inc qscmarch  charles casamento  questcor pharmaceuticals inc qscaugust  charles casamento  questcor pharmaceuticals inc qscjune  charles casamento  questcor pharmaceuticals inc qscaugust  charles j casamento  questcor pharmaceuticals inc qscjanuary  charles j casamento  ribogene inc rbofebruary   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google charles j casamento mba  executive profile  biography  bloomberg july    am et biotechnology company overview of international stem cell corporation snapshotpeople  overviewboard memberscommittees executive profile charles j casamento mba executive director international stem cell corporationagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr charles j casamento also known as chuck mba has been principal of the sage group inc since may  mr casamento has over  years of extensive experience in marketing business development and executive management in pharmaceutical biotechnology and medical products companies mr casamento served as the president and chief executive officer of osteologix holdings plc alternate name osteologix inc from october   to april   chief accounting  officer until april   and consultant from april   to july   he was founder of questcor pharmaceuticals he served as the chairman chief executive officer and president of questcor pharmaceuticals inc from november  to august   and consultant since august   prior to joining questcor pharmaceuticals inc he served as the chairman chief executive officer and president of ribogene inc from june  to november  mr casamento cofounded interneuron pharmaceuticals inc and served as its president and chief executive officer from march  to may  from july  to march  he served as the senior vice president and general manager pharmaceuticals  biochemicals at genzyme corporation from december  to march  he has held management positions at novartis johnson  johnson hoffmann laroche inc sandoz inc and american hospital supply corp where he served as the vice president business development and strategic planning for the critical care division from january  to july  he has been the chairman of relmada therapeutics inc since june   and as its independent director since july   he served as the chairman of respirerx pharmaceuticals incalso known as cortex pharmaceuticals inc from august   to march   he served as vice chairman of the catholic medical mission board he has been an executive director of the sage group inc since may  he has been a director of azurrx biopharma inc since march   he has been an independent director of astex pharmaceuticals inc alternate name supergen inc since september  and an executive director at international stem cell corporation since june   he has been a director of kinemed inc since november  he serves as a director on the boards of eight public biotechnologypharmaceutical companies he serves as a director of the catholic medical mission board in new york city a notforprofit organization he served as a director of lifepoint inc from june   to october  he served as an independent director of vivus inc from april   to july  he served as an independent director of cortex pharmaceuticals inc from july  to august   he served as a director questcor pharmaceuticals inc mr casamento served as a director of osteologix until june   he served as a director of ribogene inc he is also a licensed pharmacist in the states of new york and new jersey mr casamento holds a bachelors degree in pharmacy from fordham university and an mba degree from iona collegeread full background corporate headquarters  priestly drivecarlsbad california united statesphone fax  board members memberships presentindependent directorastex pharmaceuticals incpresentexecutive directorthe sage group incpresentexecutive directorinternational stem cell corporationpresentdirectorkinemed incpresentchairmanrelmada therapeutics incpresentdirectorazurrx biopharma inc education bs fordham universitymba iona college other affiliations endo pharmaceuticals solutions incribogene incastex pharmaceuticals incvivus increspirerx pharmaceuticals incquestcor pharmaceuticals inclifepoint incfordham universityiona collegethe sage group increlmada therapeutics inckinemed incosteologix holdings plcazurrx biopharma inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationolav hellebø mba bbachief executive officer and directorreneuron group plckmarc h hedrick mdchief executive officer president  directorcytori therapeutics inckdavid e jorden cpachief executive officer chief financial officer and executive directornuo therapeutics inckmichael tomas chief executive officer president chief financial officer and directorus stem cell incmrichard j daly chairman of the board ceo president and interim principal financial  accounting officerneuralstem inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact international stem cell corporation please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close charles j casamento appointed chairman of relmada therapeutics board of directors charles j casamento appointed chairman of relmada therapeutics board of directors globally recognized leader in drug development and commercialization assumes board leadership as relmada advances clinical development of drug candidates to treat cns disorders news provided by relmada therapeutics inc jun    et share this article new york june   prnewswire  relmada therapeutics inc otcqb rlmd a clinicalstage company developing novel therapies for the treatment of central nervous system cns diseases today announced that charles j casamento has been appointed chairman of the companys board of directors  mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committees since  mr casamento has been executive director and principal of the sage group a health care advisory group  previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals in  questcor was acquired by mallinckrodt for approximately  billion  he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus formerly interneuron pharmaceuticals in  indevus was acquired by endo pharmaceuticals for approximately  million  he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizations charles casamento has been an outstanding member of the relmada board of directors and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead said sergio traversa chief executive officer of relmada about relmada therapeutics inc relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine for more information please visit relmadas website at wwwrelmadacom  forwardlooking statements the private securities litigation reform act of  provides a safe harbor for forwardlooking statements made by us or on our behalf we may from time to time make written or oral statements in this letter the proxy statements filed with the sec communications to stockholders and press releases which constitute forwardlooking statements within the meaning of section a of the securities act of  and section e of the securities exchange act of  these forwardlooking statements are based upon managements current expectations estimates assumptions and beliefs concerning future events and conditions and may discuss among other things anticipated future performance expected product development product potential future business plans and costs any statement that is not historical in nature is a forwardlooking statement and may be identified by the use of words and phrases such as expects anticipates believes will will likely result will continue plans to and similar expressions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected relmada undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise readers are cautioned that it is not possible to predict or identify all of the risks uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list contact media contact  bill berry  berry  company public relations  tel   bberryberryprcom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescharlesjcasamentoappointedchairmanofrelmadatherapeuticsboardofdirectorshtml source relmada therapeutics inc related links httpwwwrelmadacom jun    et preview dr ottavio vitolo appointed executive clinical advisor at relmada therapeutics may    et preview relmada therapeutics announces settlement of legal action with laidlaw  company my news release contains wide tables view fullscreen also from this source jun    et relmada therapeutics appoints dr maurizio fava as chair of the jun    et dr ottavio vitolo appointed executive clinical advisor at explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals personnel announcements you just read charles j casamento appointed chairman of relmada therapeutics board of directors news provided by relmada therapeutics inc jun    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search charles j casamento  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in charles j casamento board member at international stem cell corporation view full profile are you charles j casamento claim your profile   sign up for equilar atlas and view charles j casamentos full profile with equilar atlas you can identify corporate executives in charles j casamentos network and community follow changes in charles j casamentos employment and moneyinmotion connect with charles j casamento through your network of contacts charles j casamentos executive work history current board member international stem cell corporation board member azurrx biopharma inc past to view charles j casamentos complete executive work history sign up now age      charles j casamentos biography charles j casamento has been a director since june  mr casamento is currently executive director and principal of the sage group a healthcare advisory group specializing in mergers acquisitions and partnerships between biotechnology companies and pharmaceutical companies since  he was the president and ceo of osteologix inc a public biopharmaceutical company developing products for treating osteoporosis from  through  from  through  he served as chairman of the board president and ceo of questcor pharmaceuticals inc which was subsequently acquired by mallinckrodt mr casamento formerly served as ribog  read more charles j casamento has been a director since june  mr casamento is currently executive director and principal of the sage group a healthcare advisory group specializing in mergers acquisitions and partnerships between biotechnology companies and pharmaceutical companies since  he was the president and ceo of osteologix inc a public biopharmaceutical company developing products for treating osteoporosis from  through  from  through  he served as chairman of the board president and ceo of questcor pharmaceuticals inc which was subsequently acquired by mallinckrodt mr casamento formerly served as ribogene incs president ceo and chairman of the board from  through  until it merged with cypros to form questcor he was cofounder president and ceo of interneuron pharmaceuticals inc indevus a biopharmaceutical company from  until  indevus was eventually acquired by endo mr casamento has also held senior management positions at genzyme corporation where he was senior vice president pharmaceuticals and biochemicals american hospital supply where he was vice president of business development and strategic planning for the critical care division johnson  johnson hoffmannlaroche inc and sandoz inc mr casamento also serves on the board of directors of relmada therapeutics and azurrx biopharma he is chairman of the audit committee at relmada during his career he has sat on the boards of twelve public companies and has also been a director and vice chairman of the catholic medical missions board a large not for profit organization providing health care services to third world countries he has served as a guest lecturer at fordham university and is on the science council of fordham university he holds a bachelors degree in pharmacy from fordham university and an mba from iona college and was originally licensed to practice pharmacy in the states of new york and new jersey we believe that mr casamentos qualifications to serve on our board include his significant experience as chief executive officer in various life sciences companies and his service on several other boards which bring valuable knowledge and insights to the board source international stem cell corporation on    sign up for equilar atlas and view charles j casamentos full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like charles j casamento more specifically youll be able to identify corporate executives in charles j casamentos network and community follow changes in charles j casamentos employment and moneyinmotion connect with charles j casamento through your network of conections view full profile   search for over  executive profiles bio example charles j casamento charles j casamentos connections  sign up now to view charles j casamentos  connections » denis r burger chief science officer and vice chairman of the board cytodyn inc roger g stoll chairman of the board delcath systems inc jeffrey d janus former consultant international stem cell corporation martin buckland former chief business officer astex pharmaceuticals allan r goldberg former board member astex pharmaceuticals brian lundstrom former employee international stem cell corporation ismail kola board member athersys inc mario m rosati board member sanmina corporation john f benedik former board member respirerx timothy haines former board member sientra inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   charles j casamento appointed chairman of relmada therapeutics board of directors  gurufocuscom charles j casamento appointed chairman of relmada therapeutics board of directors  gurufocuscom home homepage membership levels membership data coverage complete stock list founders message the book free trial screeners value screens allinone screener industry overview ben graham netnet undervalued predictable buffettmunger screener magic formula greenblatt historical low ps list historical low pb list peter lynch screen high short interest weekyy lows weekyy highs predictable companies sp  grid dividend stocks spin off list downloads  tools excel addin guruf manual of stocks™ download financial data download guru portfolios download stock pdfs download insider data api mobile app strategies performances buffettmunger undervalued predictable low ps low pb broadest owned most weighted gurus latest guru picks real time picks list of gurus personalize gurus portfolios scoreboard top  holdings view sector picks international picks aggregated portfolio consensus picks guru bargains hot picks industry trends geographic trend etfs options european shorting insiders all insiders ceo buyssales cfo buyssales insider cluster guruinsider double buys triple buyssales insider trends canadian insider dutch insider market market valuation economic data industry overview marketcapgdp valuation global market valuation shiller pe shiller pe by sectors buffett assets allocation by country usa australia canada china germany india japan uk more articles articles editors picks gurufocus research value ideas interviews with gurus top ranked value idea contest videos following authors submit articles writers wanted value contest winners submit articles online my articles conference value conference speakers locationvenue register after conference gathering free drinks tutorials tutorials  webinars faq contact us log in free signup log in day free trial subscribe free trial year refer a friend  earn  search compare search ▾ get day free trial my portfolios▾ portfolios overview create new portfolio portfolio contest my gurus▾ quick browse personalize my gurus premium gurus premium plus investors how to use gurufocus  tutorials what is in the gurufocus premium membership a diy guide on how to invest using guru strategies prnewswirearticles  bookmark print tweet bookmark name this page was added to your bookmark members only please sign up or log in first bookmark of this page has been deleted charles j casamento appointed chairman of relmada therapeutics board of directorsjune    about otcpkrlmd  otcpkrlmd  otcpkrlmd  globally recognized leader in drug development and commercialization assumes board leadership as relmada advances clinical development of drug candidates to treat cns disorders pr newswire new york june   new york june   prnewswire  relmada therapeutics inc otcqb rlmd a clinicalstage company developing novel therapies for the treatment of central nervous system cns diseases today announced that charles j casamento has been appointed chairman of the companys board of directors mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committees warning gurufocus has detected  warning signs with otcpkrlmd click here to check it out otcpkrlmd year financial datathe intrinsic value of otcpkrlmdpeter lynch chart of otcpkrlmd since  mr casamento has been executive director and principal of the sage group a health care advisory group previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals in  questcor was acquired by mallinckrodt for approximately  billion he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus formerly interneuron pharmaceuticals in  indevus was acquired by endo pharmaceuticals for approximately  million he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizations charles casamento has been an outstanding member of the relmada board of directors and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead said sergio traversa chief executive officer of relmada about relmada therapeutics inc relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine for more information please visit relmadas website at wwwrelmadacom forwardlooking statements the private securities litigation reform act of  provides a safe harbor for forwardlooking statements made by us or on our behalf we may from time to time make written or oral statements in this letter the proxy statements filed with the sec communications to stockholders and press releases which constitute forwardlooking statements within the meaning of section a of the securities act of  and section e of the securities exchange act of  these forwardlooking statements are based upon managements current expectations estimates assumptions and beliefs concerning future events and conditions and may discuss among other things anticipated future performance expected product development product potential future business plans and costs any statement that is not historical in nature is a forwardlooking statement and may be identified by the use of words and phrases such as expects anticipates believes will will likely result will continue plans to and similar expressions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected relmada undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise readers are cautioned that it is not possible to predict or identify all of the risks uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list contact media contact bill berry berry  company public relations tel  email protected to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescharlesjcasamentoappointedchairmanofrelmadatherapeuticsboardofdirectorshtml source relmada therapeutics inc currently  rating   votes subscribe via email subscribe rss comments please leave your comment more gurufocus links latest guru picks value strategies warren buffett portfolio ben graham netnet real time picks buffettmunger screener aggregated portfolio undervalued predictable etfs options low ps companies insider trends year financials week lows interactive charts model portfolios dcf calculator rss feed monthly newsletters the allinone screener portfolio tracking tool gurufocus has detected  warning signs with relmada therapeutics inc otcpkrlmd more than  people have already joined gurufocus to track the stocks they follow and exchange investment ideas →performances of the stocks mentioned by prnewswire →user generated screeners portfolioplus yr profitabilitytaekgyun kovalueportfolioplusstrong bs screenconnormcommodityconnormlosingexusconnormlosingholklsumini group it healthcare materluddyshooting starspeterzmiihkfilmwatcherstable dividend growers →otcpkrlmd price chart  y  →guru newsshould you believe in targets turnaround by harsh jain investment ideas from industry insiders by bram de haaswhy investors should consider pepsico by mayank marwahheres why you should pay attention to carters by omar venerio→value ideas investment ideas from industry insiders by bram de haaswhy investors should consider pepsico by mayank marwahheres why you should pay attention to carters by omar veneriovoya financial a risky financial bet by mark yu→guru interviewspodcast episode  healthcare investing pro mindy perry by holly lafonpodcast episode  interview with legendary investor jeanmarie eveillard by holly lafon questions with the founder of wayundervaluedcom by pj pahygiannisgurufocus interview orbimed guru sam isaly on investing in new era of healthcare by holly lafon→top ranked articlessome thoughts on holding cash by the science of hittingmohnish pabrai crushing it with  bestperforming car companies ferrari and fiat by holly lafonberkshire and blue chip stamps by the science of hittingwhat can we learn from the energy market by grahamites →you may also likerelmada announces fda fast track designation for dmethadone for adjunctive treatment of major depressive disorderdell technologies championship bostonarea charity partners namedinfrareit announces agreements for simultaneous rate case dismissal and the exchange of retail distribution assets for transmission assets from oncordebra deshong joins mgm resorts international as vice president of global industry affairsdelmar pharmaceuticals receives approval from chinas human genetic resources administration to initiate phase  clinical trial in newly diagnosed gbm select portfolios create a new portfolio why you are interested your selection and notes will be stored in your portfolio login to add portfolio get wordpress plugins for easy affiliate links on stock tickers and guru names  earn affiliate commissions by embedding gurufocus charts gurufocus affiliate program earn up to  per referral  learn more home  about   jobs   advertise    site map    term of use    privacy policy     rss    mobile app     email alerts    referral program    affiliate program    faq    contact us      gurufocuscom llc all rights reserved disclaimers gurufocuscom is not operated by a broker a dealer or a registered investment adviser under no circumstances does any information posted on gurufocuscom represent a recommendation to buy or sell a security the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the gurus may buy and sell securities before and after any particular article and report and information herein is published with respect to the securities discussed in any article and report posted herein in no event shall gurufocuscom be liable to any member guest or third party for any damages of any kind arising out of the use of any content or other material published or available on gurufocuscom or relating to the use of or inability to use gurufocuscom or any content including without limitation any investment losses lost profits lost opportunity special incidental indirect consequential or punitive damages past performance is a poor indicator of future performance the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the information on this site is in no way guaranteed for completeness accuracy or in any other way the gurus listed in this website are not affiliated with gurufocuscom llc stock quotes provided by interactive data fundamental company data provided by morningstar updated daily gf chat  × manage bookmarks close feedback charles j casamento  ribogene inc rbo  the wall street transcript healthcare  ceo interviews  february   charles j casamento – ribogene inc rbo charles j casamento is chairman president and chief executive officer of questcor pharmaceuticals inc he joined ribogene inc in june  on november   ribogene and cypros merged to form questcor pharmaceuticals inc the company currently has five products on the market in the us in the fourth quarter of  driven by the introduction of a new product nascobal questcor revenues hit a record level and the company recorded its first profitable quarter with net income of  mr casamento closed  partnership product acquisition rd collaborations and merger transactions with questcor previously mr casamento was president and chief executive officer of interneuron pharmaceuticals inc which he cofounded in february  from  to  he was senior vice president at genzyme corporation from  to  he was vice president business development and planning at the critical care division of american hospital supply corporation and from  to  he held managerial positions with johnson  johnson hoffmannlaroche and sandoz mr casamento received an mba in  from iona college new rochelle new york and a bs in pharmacy in  from fordham university college of pharmacy in new york city he is a member of the board of directors of cortex pharmaceuticals inc in irvine california supergen inc in dublin california and the catholic medical mission board a nonprofit organization in new york new york which serves the medical needs of people in third world countries he is a licensed pharmacist in the states of new york and new jersey profile twst first give us a background summary on the company enoughinformation to put us into context as what you see as your business andwhat you see as your company today mr casamento join for free to read a longer excerpt or purchase this article already a member login here  cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google charles j casamento appointed chairman of relmada therapeutics board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       charles j casamento appointed chairman of relmada therapeutics board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs new york june  prnewswire  relmada therapeutics inc otcqb rlmd a clinicalstage company developing novel therapies for the treatment of central nervous system cns diseases today announced that charles j casamento has been appointed chairman of the companys board of directors mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committeessince  mr casamento has been executive director and principal of the sage group a health care advisory group previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals in  questcor was acquired by mallinckrodt for approximately  billion he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus formerly interneuron pharmaceuticals in  indevus was acquired by endo pharmaceuticals for approximately  million he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizations charles casamento has been an outstanding member of the relmada board of directors and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead said sergio traversa chief executive officer of relmadaabout relmada therapeutics inc relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine for more information please visit relmadas website at wwwrelmadacom forwardlooking statements the private securities litigation reform act of  provides a safe harbor for forwardlooking statements made by us or on our behalf we may from time to time make written or oral statements in this letter the proxy statements filed with the sec communications to stockholders and press releases which constitute forwardlooking statements within the meaning of section a of the securities act of  and section e of the securities exchange act of  these forwardlooking statements are based upon managements current expectations estimates assumptions and beliefs concerning future events and conditions and may discuss among other things anticipated future performance expected product development product potential future business plans and costs any statement that is not historical in nature is a forwardlooking statement and may be identified by the use of words and phrases such as expects anticipates believes will will likely result will continue plans to and similar expressions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected relmada undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise readers are cautioned that it is not possible to predict or identify all of the risks uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete listcontactmedia contact bill berry berry  company public relations tel  bberryberryprcomto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescharlesjcasamentoappointedchairmanofrelmadatherapeuticsboardofdirectorshtmlsource relmada therapeutics inc read at biospacecom related news relmada therapeutics announces settlement of legal action with laidlaw  company aziyo biologics banks some cash and former osiris osir exec as its new ceo relmada therapeutics announces fda fast track designation for dmethadone for adjunctive treatment of major depressive disorder effective immediately bristolmyers squibb bmy exec to take the reins at kleo relmada therapeutics release announces fda acceptance of ind and authorization to commence phase a clinical trial for dmethadone what would  industry icons do differently if given the chance to be ceo again relmada therapeutics release pharma to provide an update on the development plan for levocap er alexion alxn poaches biogen biibs longtime cfo relmada therapeutics announces issuance of key us patent covering dmethadone an nmda receptor antagonist for the treatment of depression and other psychiatric symptoms struggling teva teva wants to overhaul board by nominating  new directors please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • relmada therapeutics   • biotechpharma  personnel                 charles j casamento appointed chairman of relmada therapeutics board of directors  relmada therapeutics inc rlmd press releases investors home investors news  events press releases charles j casamento appointed chairman of investors charles j casamento appointed chairman of relmada therapeutics board of directors download as pdf june   globally recognized leader in drug development and commercialization assumes board leadership as relmada advances clinical development of drug candidates to treat cns disorders new york june   prnewswire  relmada therapeutics inc otcqb rlmd a clinicalstage company developing novel therapies for the treatment of central nervous system cns diseases today announced that charles j casamento has been appointed chairman of the companys board of directors  mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committees since  mr casamento has been executive director and principal of the sage group a health care advisory group  previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals in  questcor was acquired by mallinckrodt for approximately  billion  he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus formerly interneuron pharmaceuticals in  indevus was acquired by endo pharmaceuticals for approximately  million  he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizations charles casamento has been an outstanding member of the relmada board of directors and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead said sergio traversa chief executive officer of relmada about relmada therapeutics inc relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine for more information please visit relmadas website at wwwrelmadacom  forwardlooking statements the private securities litigation reform act of  provides a safe harbor for forwardlooking statements made by us or on our behalf we may from time to time make written or oral statements in this letter the proxy statements filed with the sec communications to stockholders and press releases which constitute forwardlooking statements within the meaning of section a of the securities act of  and section e of the securities exchange act of  these forwardlooking statements are based upon managements current expectations estimates assumptions and beliefs concerning future events and conditions and may discuss among other things anticipated future performance expected product development product potential future business plans and costs any statement that is not historical in nature is a forwardlooking statement and may be identified by the use of words and phrases such as expects anticipates believes will will likely result will continue plans to and similar expressions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected relmada undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise readers are cautioned that it is not possible to predict or identify all of the risks uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list contact media contact  bill berry  berry  company public relations  tel   bberryberryprcom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescharlesjcasamentoappointedchairmanofrelmadatherapeuticsboardofdirectorshtml source relmada therapeutics inc released june   charles j casamento appointed chairman of relmada therapeutics board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  minssp futures dow futuresundefined nasdaq futures charles j casamento appointed chairman of relmada therapeutics board of directorspr newswirejune  reblogsharetweetshareglobally recognized leader in drug development and commercialization assumes board leadership as relmada advances clinical development of drug candidates to treat cns disordersnew york june   prnewswire  relmada therapeutics inc rlmd a clinicalstage company developing novel therapies for the treatment of central nervous system cns diseases today announced that charles j casamento has been appointed chairman of the companys board of directors  mr casamento has been a member of the relmada therapeutics board of directors since july  and is also chairman of the audit committee and a member of the compensation and the corporate governance committeesrelmada therapeutics corporate logomoresince  mr casamento has been executive director and principal of the sage group a health care advisory group  previously he was president and ceo of osteologix and founder chairman and ceo of questcor pharmaceuticals in  questcor was acquired by mallinckrodt for approximately  billion  he also served as president ceo and chairman of ribogene inc and was cofounder president and ceo of indevus formerly interneuron pharmaceuticals in  indevus was acquired by endo pharmaceuticals for approximately  million  he has also held senior management positions at genzyme corporation american hospital supply johnson  johnson hoffmannlaroche and sandoz he has served as a director of eleven other pharmaceuticalbiotechnology companies and has been on the board of two not for profit organizationscharles casamento has been an outstanding member of the relmada board of directors and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead said sergio traversa chief executive officer of relmadaabout relmada therapeutics inc relmada therapeutics is a clinicalstage publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system cns diseases the company has a diversified portfolio of four products at various stages of development including dmethadone dextromethadone rel an nmethyldaspartate nmda receptor antagonist for depression and neuropathic pain levocap er rel an abuse resistant sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine butab rel an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine mepigel rel an orphan drug designated topical formulation of the local anesthetic mepivacaine for more information please visit relmadas website at wwwrelmadacom  forwardlooking statements the private securities litigation reform act of  provides a safe harbor for forwardlooking statements made by us or on our behalf we may from time to time make written or oral statements in this letter the proxy statements filed with the sec communications to stockholders and press releases which constitute forwardlooking statements within the meaning of section a of the securities act of  and section e of the securities exchange act of  these forwardlooking statements are based upon managements current expectations estimates assumptions and beliefs concerning future events and conditions and may discuss among other things anticipated future performance expected product development product potential future business plans and costs any statement that is not historical in nature is a forwardlooking statement and may be identified by the use of words and phrases such as expects anticipates believes will will likely result will continue plans to and similar expressions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected relmada undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise readers are cautioned that it is not possible to predict or identify all of the risks uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete listread morecontactmedia contact  bill berry  berry  company public relations  tel   bberryberryprcomto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescharlesjcasamentoappointedchairmanofrelmadatherapeuticsboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextgrab builds out war chest in a fight for carshare dominanceassociated pressa big fall in markets is coming as traders put record cash to workbusiness insiderhere’s the next ‘fang’ stock that’s set to explodecnbc years after korean war north still digging up bombsassociated pressaetna ceo bertolini how tech plays into the future of healthcareyahoo finance videoaetnas ceo mark bertolini on the future of the health care systemyahoo financehow  lifethreatening events changed how aetnas ceo views health careyahoo financeblue apron just got a flood of bullish ratings from wall street and its shares are flyingbusiness insiderwhy sparkling water sales could spike by  in yahoo financeaetna ceo bertolini why he pays his employees to sleepyahoo finance videowhy it might be ‘dangerous’ for ibm to turn itself around professoryahoo financeamazon is going underwater seriouslyfortunejeb bush calls out republicans who criticized obama over russia but have been silent on the trumprussia probebusiness insiderkkr to buy webmd in  billion dealreutersaetna ceo bertolini how his own accident and son’s cancer changed his journeyyahoo finance videocall of the week nows the time to buy chipotleyahoo finance years after korean war north still digging up bombsjames well you should not have tried to push communism onto the south now should youjoin the conversation